Conivaptan - Cumberland Pharmaceuticals

Drug Profile

Conivaptan - Cumberland Pharmaceuticals

Alternative Names: CI-1025; Vaprisol; YM-087

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Astellas Pharma
  • Developer Alliance Healthcare; Cumberland Pharmaceuticals; DB Pharm Korea; Piramal Critical Care
  • Class Benzazepines; Small molecules
  • Mechanism of Action Vasopressin 1 receptor antagonists; Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyponatraemia
  • Discontinued Heart failure

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 04 Apr 2016 Cumberland Pharmaceuticals and Clinigen enter into a licensing agreement to develop Vaprisol® (Cumberland Pharmaceuticals, Form 10-K, March 2016)
  • 14 Mar 2016 Cumberland Pharmaceuticals and Alliance Pharm PTE enter into a marketing license agreement for Vaprisol® in Singapore (Cumberland Pharmaceuticals, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top